Back to results
US 9,066,899 B2Granted
Vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorsWilliam Ripley Ballou, Joseph D Cohen
Life of this patent
Estimating the term…
Abstract
The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria.
Claims15
A method for inducing an immune response against Plasmodium falciparum in an infant comprising
- a) selecting an infant from about 1 week old to about 50 weeks old and is at risk of malaria disease or infection;
- and
- b) administering an immunogenic composition comprising
- i) a fusion protein comprising a polypeptide comprising a Plasmodium falciparum circumsporozoite protein (CS) antigen or an immunogenic fragment thereof comprising substantially all the C-terminal portion of the CS protein and four or more tandem repeats of the CS protein immunodominant region;
- and
- hepatitis B surface antigen (HBsAg), and
- ii) a pharmaceutically acceptable adjuvant comprising 3-O-deacylated monophosphoryl lipid A (3D-MPL), and QS21,
- wherein the CS antigen is expressed at the pre-erythrocytic stage of malarial infection.
5 more elements
A method for treating, preventing or reducing the incidence of clinical malaria in an infant comprising
- a) selecting an infant from about 1 week old to about 50 weeks old and is at risk of malaria disease or infection;
- and
- b) administering an immunogenic composition comprising
- i) a fusion protein comprising a polypeptide comprising
- a Plasmodium falciparum circumsporozoite protein (CS) antigen or an immunogenic fragment thereof comprising substantially all the C-terminal portion of the CS protein and four or more tandem repeats of the CS protein immunodominant region;
- and
- hepatitis B surface antigen (HBsAg), and
- ii) a pharmaceutically acceptable adjuvant comprising
- 3-O-deacylated monophosphoryl lipid A (3D-MPL), and QS21,
- wherein the CS antigen is expressed at the pre-erythrocytic stage of malarial infection.
7 more elements
Dependencies are inferred from the claim text.